


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

LISTING OF CLAIMS:

1.-7. (cancelled).


8. (currently amended) An isolated A-compound of the formula:



Compound 2(a)


or a pharmaceutically acceptable salt thereof.

9. (currently amended) An isolated A-compound of the formula II:



Formula II

wherein A¹ is -NH₂, -N=CH-R¹³, an amino acid or -NH-R¹⁴, wherein R¹³ is hydrogen or phenyl, wherein the amino acid is attached via its nitrogen atom, and wherein R¹⁴ is selected from the group consisting of isopropyl, 1-(4-nitrophenyl)methyl, cyclohexyl,




wherein R¹⁵ is selected from the group consisting of methyl, isopropyl, phenyl, 4-nitrophenyl, 1-aminoethyl, 1-amino-1-(4-hydroxyphenyl)methyl, 1-amino-2-(4-


Appln. Serial No.: 10/760,493

hydroxyphenyl)ethyl, 1-amino-2-methylpropyl, 2-pyrrolidinyl and 1-amino-2-hydroxyethyl;

Z¹ is selected from the group consisting of:




R²⁰ is selected from the group consisting of hydrogen and




; and

D¹ is hydroxy, methoxy or




and pharmaceutically acceptable salts thereof.


10. (currently amended) An isolated A-compound selected from the group consisting of:




Compound 2(c)




Compound 2(d)




Compound 2(e)




Compound 2(g)




Compound 2(h)




Compound 2(i)




Compound 2(j)




Compound 2(n)




Compound 2(o)




Compound 2(p)




Compound 2(q)




Compound 2(r)




Compound 2(s)




Compound 2(t)




Compound 2(u)




Compound 2(v)




Compound 2(w)




Compound 2(x)




Compound 2(y)



Compound 2(z)



Compound 2(aa)



11. (previously presented) A method for obtaining the compound of claim 8, comprising:

- (a) culturing cells derived from a *Streptomyces aizunensis* strain aerobically and in a growth medium, whereby the compound of claim 8 is produced,
- (b) extracting said medium of (a) with a solvent, and
- (c) purifying the compound of claim 8 from the extract of (b), thereby obtaining the compound of claim 8.

12. (original) The method of claim 11 wherein said *Streptomyces aizunensis* strain is NRRL B-11277 or a mutant thereof.

13. (original) The method of claim 12 wherein said mutant is strain [C03]023 (deposit accession number IDAC 070803-1) or [C03U03]023 (deposit accession number IDAC 231203-02).

14.-15. (canceled).

16. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 10, and a pharmaceutically acceptable carrier.

17. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 8, and a pharmaceutically acceptable carrier.

18. (currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 9, and a pharmaceutically acceptable carrier.

19. (previously presented) A method of treating a fungal infection in a mammal, comprising administering to a mammal having a fungal infection a therapeutically effective amount of a compound of claim 8.

20. (original) The method of claim 19 wherein said fungal infection is caused by *Candida albicans*.

21. (original) The method of claim 19 wherein said fungal infection is caused by a *Candida* sp., wherein said *Candida* sp. is selected from the group consisting of *C. glabrata*, *C. lusitaniae*, *C. parapsilosis*, *C. krusei* and *C. tropicalis*.

22. (original) The method of claim 19 wherein said fungal infection is caused by an *Aspergillus* sp., wherein said *Aspergillus* sp. is selected from the group consisting of *A. fumigatus*, *A. niger*, *A. terreus* and *A. flavus*.

23. (previously presented) The method of claim 19 wherein said fungal infection is caused by a fungus selected from the group consisting of *Fusarium* spp.; *Scedosporium* spp.; *Cryptococcus* spp.; *Mucor* spp.; *Histoplasma* spp.; *Trichosporon* spp.; *Blasopomyces* spp.; and *S. cerevisiae*.

24. (previously presented) A method of treating a fungal infection in a mammal, comprising administering to a mammal having a fungal infection a therapeutically effective amount of a compound of claim 9.

25. (previously presented) The method of claim 24 wherein said fungal infection is caused by *Candida albicans*.

26. (previously presented) The method of claim 24 wherein said fungal infection is caused by a *Candida* sp., wherein said *Candida* sp. is selected from the group consisting of *C. glabrata*, *C. lusitaniae*, *C. parapsilosis*, *C. krusei* and *C. tropicalis*.

27. (previously presented) The method of claim 24 wherein said fungal infection is caused by an *Aspergillus* sp., wherein said *Aspergillus* sp. is selected from the group consisting of *A. fumigatus*, *A. niger*, *A. terreus* and *A. flavus*.

28. (previously presented) The method of claim 24 wherein said fungal infection is caused by a fungus selected from the group consisting of *Fusarium* spp.; *Scedosporium* spp.; *Cryptococcus* spp.; *Mucor* spp.; *Histoplasma* spp.; *Trichosporon* spp.; *Blasopomyces* spp.; and *S. cerevisiae*.

29. (previously presented) A method of treating a fungal infection in a mammal, comprising administering to a mammal having a fungal infection a therapeutically effective amount of a compound of claim 10.

30. (previously presented) The method of claim 29 wherein said fungal infection is caused by *Candida albicans*.

31. (previously presented) The method of claim 29 wherein said fungal infection is caused by a *Candida* sp., wherein said *Candida* sp. is selected from the group consisting of *C. glabrata*, *C. lusitaniae*, *C. parapsilosis*, *C. krusei* and *C. tropicalis*.

32. (previously presented) The method of claim 29 wherein said fungal infection is caused by an *Aspergillus* sp., wherein said *Aspergillus* sp. is selected from the group consisting of *A. fumigatus*, *A. niger*, *A. terreus* and *A. flavus*.

33. (previously presented) The method of claim 29 wherein said fungal infection is caused by a fungus selected from the group consisting of *Fusarium* spp.; *Scedosporium* spp.; *Cryptococcus* spp.; *Mucor* spp.; *Histoplasma* spp.; *Trichosporon* spp.; *Blasporomyces* spp.; and *S. cerevisiae*.